Mounjaro might be the next drug—after Ozempic—to upend the weight-loss market after a study showed it helped overweight and obese patients with Type 2 diabetes lose up to 15.7% of their body weight
Illustration: Elizabeth SmelovEli Lilly & Co.’s drug Mounjaro for Type 2 diabetes helped people who are also overweight or obese lose up to 15.
7% of their body weight, in a new study that could pave the way for Lilly to promote the drug asIndianapolis-based Lilly said that with the new data, it will complete in the coming weeks an application to the U.S. Food and Drug Administration to market Mounjaro as an anti-obesity treatment, which could enable an FDA decision by the end of the year.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Popular diabetes drug Mounjaro could be FDA-approved for weight loss this year, company saysA popular drug currently approved to treat Type 2 diabetes could soon also be approved for weight loss.
Baca lebih lajut »
What Are the Healthiest Drinks for Patients With Type 2 Diabetes?People with T2D who drink large amounts of sugary beverages face an increased risk of cardiovascular disease and all-cause death compared with those who stick to healthier options. Diabetes EndoTwitter
Baca lebih lajut »
Powerful new obesity drug poised to upend weight loss careA diabetes drug being tested for weight loss is poised to further upend obesity care. Drugmaker Eli Lilly and Co. reported Thursday that its drug tirzepatide helped people with diabetes who were overweight or had obesity lose up to 16% of their body weight over 17 months in a late-stage trial. For those without the disease, the drug has prompted losses of more than 20% of body weight. Known as Mounjaro for diabetes use, the drug has been used “off label” for weight loss since last year. Lilly is applying for fast-track approval from U.S. regulators and expects a decision this year. Analysts have predicted tirzepatide could become one of the top-selling drugs ever, with annual sales of more than $50 billion.
Baca lebih lajut »
Eli Lilly’s tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in late-stage trialEli Lilly & Co. said Thursday its tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in a late-stage...
Baca lebih lajut »
Citizens United for Harvey's Youth takes teens in the right directionCitizens United for Harvey\u0027s Youth helps teens
Baca lebih lajut »
Galaxy interactions are the dominant trigger for local type 2 quasarsABSTRACT. The triggering mechanism for the most luminous, quasar-like active galactic nuclei (AGN) remains a source of debate, with some studies favouring trigg
Baca lebih lajut »